about
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.VAV3 mediates resistance to breast cancer endocrine therapy.Study of breast cancer incidence in patients of lymphangioleiomyomatosis.CD 30-positive transformed follicular lymphoma: two case reports and literature review.Small-cell predominant extranodal NK/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population.Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy.[Positron emission tomography combined with computed tomography in the initial evaluation and response assessment in primary central nervous system lymphoma].Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases.LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.Metaplastic carcinoma of the breast with chondroid differentiation (matrix-producing carcinoma): study of the diagnostic cost-effectiveness of fine-needle aspiration biopsy and needle core biopsy.Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessThe PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patientsPharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphomaClinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapyCutaneous Nodules in Multiple Myeloma. Cutaneous plasmacytoma associated with multiple myelomaPrimary cutaneous vs secondary cutaneous follicular lymphomas: A comparative study focused on BCL2, CD10, and t(14;18) expressionCCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphomaCorrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single InstitutionValidation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institutionAllogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationAutologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMTDiffuse large B cell lymphoma associated with methotrexate in a patient with acute lymphoblastic leukemiaClinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institutionLong-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutionsClinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome[Multisystem histiocytosis of Langerhans cells associated with Lymphomatoid papulosis: An accidental finding? Case report and literature review]PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institutionm7FLIPI and targeted sequencing in high-risk follicular lymphoma
P50
Q33659361-2FA41135-F45A-478D-BB80-7F9C35F9FB77Q33827037-F2468F5D-A4DF-4BC3-8B7B-817AD037E2E5Q36678521-BF886DB6-3005-4F63-8C00-3E21B4A6AFD7Q38466350-5888AF65-BC55-4A1D-B6BA-C00955895BBBQ40688247-6FDF5549-35CD-446D-A1CE-AAAA94AD88A9Q41684660-1D9E1942-A060-404E-B002-7AEA7D32A09FQ43454344-0468949D-FDB1-4A5B-89C0-AC4B9419FE95Q45957538-23981767-68A2-4FF6-B3DF-BED9446F73A6Q51100609-649A1E2C-9287-4F17-A5DD-3FBB56CEC72EQ53147519-A95819A4-1D45-4A6A-8BD6-B5B91DCE5545Q54578799-AB816A19-E4D7-4A15-AA60-D7012020F8BEQ59129769-048C0EEC-3FB0-47C3-8917-4F34C1F96913Q64042835-5C10760A-A126-4E2E-A489-EA8AF4CB5A23Q64092524-EB8551DC-3017-43E2-968E-F6836B30029BQ85211329-EE9DA586-C623-436D-968F-F96C3329578BQ87231757-F97542CC-DAAA-45DE-A4E1-9FACA530F2D0Q90237747-4043C59D-D5ED-4015-9BA0-7FEB4E15488DQ90411105-7300B66A-B9B9-4BD3-80C9-FA478ED0B8CDQ90620868-91980E8B-758E-422E-94CC-35293CA5957AQ91100890-188B4F30-5B92-4C7E-8641-6ABB351FA995Q91152150-5F956C8A-6F58-44BA-BA20-B58FECD9F526Q91152154-7F5C0EA6-26AA-4F83-A489-1F708D18D19CQ91270985-20FE7898-88F0-4FF9-B112-663C80BA7908Q91379118-0DC12C4C-7628-429E-8B38-4809594BBE75Q91460358-4B1AB19E-E213-4CC5-9DC2-EBC68A69D97FQ92300679-EA4C5188-696E-4976-BDED-6AABE4AA0C32Q92560750-92675725-9A29-4D0C-BC2B-3FB447DAD032Q92860007-0A6FA98C-8033-4BCE-B7B8-B2942AA5C00BQ93049877-56407A9F-3502-4494-9384-DCA664696575
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Fina Climent
@en
Fina Climent
@nl
type
label
Fina Climent
@en
Fina Climent
@nl
prefLabel
Fina Climent
@en
Fina Climent
@nl
P31
P496
0000-0002-4360-8388